论文部分内容阅读
GlaxoWellcome公司的曲格列酮（trogli－tazone，商品名Romozin）已在英国获得许可用于治疗非胰岛素依赖型糖尿病（NIDDM），可以单独使用，也可以与磷酸晚类药物或胰岛素联用。英国将是其它许可批准的参照国。本品1998年可能在整个欧洲上市。本品的治疗费用估计为每年每人ZOOO
GlaxoWellcome’s trogli-tazone (Romozin) is licensed in the UK for the treatment of non-insulin-dependent diabetes mellitus (NIDDM) and can be used alone or in combination with a phosphate late class drug or insulin. Britain will be a reference country for other permits. This product may be listed in Europe in 1998. The cost of this product is estimated to be ZOOO per person per year